TriLink® CleanCap® Beta gal mRNA

Supplier: TriLink BioTechnologies

L-7608-5 L-7608-100 L-7608-1000
SOLUL-7608-5EA 5750 GBP
SOLUL-7608-5 SOLUL-7608-100 SOLUL-7608-1000
TriLink® CleanCap® Beta gal mRNA
Protein Expression Protein Expression Reagents

β-galactosidase (β-gal), a protein product of the bacterial LacZ gene, catalyzes the conversion of β-galactosides into monosaccharides. β-gal is a common marker gene used to assess transfection efficiency.


  • Capped with CleanCap® AG cap analog, no base modifications in the sequence

  • Cap 1 structure with >95% capping efficiency for superior in vivo activity compared to Cap-0 mRNAs

  • Manufactured with TriLink’s proprietary CleanScript® method to lower dsRNA for improved performance

  • Ready to use in downstream mRNA applications and formulations

  • Grade: RUO


This mRNA is capped using CleanCap® Reagent AG, TriLink's co-transcriptional capping technology, which results in the naturally occurring Cap-1 structure with >95% capping efficiency. It is manufactured using TriLink’s CleanScript® method, polyadenylated, and optimised for mammalian systems. It mimics a fully processed mature mRNA.



CleanCap Reagent AG produces a base-modified Cap-1 mRNA, which shows superior in vivo activity compared to Cap-0 mRNA produced by legacy capping methods such as mCap or anti-reverse cap analog (ARCA).



CleanScript method is TriLink’s proprietary in vitro transcription process that is optimised to minimise dsRNA formation and increase mRNA activity in vivo.



Caution: Item will be delivered at or below −40 °C and should be stored at or below −40 °C.

Order Now


Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR